417722-95-3

Basic information

• Product Name: phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate
• Synonyms: phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate;Phenyl N-(4-(6-carbamoyl-7-methoxy-4-quinolyl)oxy-2-chlorophenyl)carbamate;Carbamic acid,[4-[[6-(aminocarbonyl)-7-methoxy-4-quinolinyl]oxy]-2-chlorophenyl]-,phenyl ester;Lenvatinib Intermediates 2
• CAS NO: 417722-95-3
• Molecular Formula: C₂₄H₁₈ClN₃O₅
• Molecular Weight: 463.86982
• EINECS: -0
• Mol File: 417722-95-3.mol

Chemical Properties

• Boiling Point: 644.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.418±0.06 g/cm3(Predicted)
• PKA: 11.16±0.70(Predicted)
• CAS DataBase Reference: phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate(417722-95-3)
• EPA Substance Registry System: phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate(417722-95-3)

Safety Data

• Hazardous Substances Data: 417722-95-3(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Synthesis:
Phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate is used as an intermediate in the synthesis of Descyclopropyl Lenvatinib (D288150), a metabolite of Lenvatinib (L329400). Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases, including VEGF, FGF, and SCF receptors. phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate plays a crucial role in the development of drugs that can potentially treat various cancers by targeting these receptors.
2. Used in Anticancer Applications:
As a part of the synthesis process for Descyclopropyl Lenvatinib, phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate contributes to the development of anticancer drugs. These drugs can be employed in the treatment of various types of cancer by inhibiting the activity of receptor tyrosine kinases, which are often overexpressed in cancer cells, leading to uncontrolled cell growth and tumor formation.
3. Used in Drug Delivery Systems:
Phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate, through its role in the synthesis of Descyclopropyl Lenvatinib, may also be involved in the development of novel drug delivery systems. These systems aim to improve the bioavailability, delivery, and therapeutic outcomes of the final drug product by employing various organic and metallic nanoparticles as carriers.

Upstream product

• 417724-81-3 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxamide 
• 417722-93-1 4?(4?amino?3?chlorophenoxy)?7?methoxyquinoline?6?carboxamide 
• 1885-14-9 phenyl chloroformate 
• 205448-65-3 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid methyl ester 
• 205448-66-4 methyl 4-chloro-7-methoxyquinoline-6-carboxylate 
• 417721-36-9 4‐chloro‐7‐methoxyquinoline‐6‐carboxamide 
• 52671-64-4 4-Amino-3-chlorophenol hydrochloride 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 205448-64-2 methyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)-amino)-2-methoxybenzoate 
• 17609-80-2 4-amino-3-chlorophenol 
• 157898-12-9 C₁₁H₉NO₅ 
• 17175-11-0 phenyl O‐(4‐nitrophenyl) carbonate 

Downstream Products

• 417716-92-8 lenvatinib 
• 417719-47-2 4-(3-chloro-4-(1-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 
• 417719-51-8 4-(3-Chloro-4-(aminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 
• 417719-46-1 4-[3-chloro-4-(ethylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 
• 417719-48-3 4-(3-Chloro-4-(cyanomethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 
• 417719-45-0 4-[3-chloro-4-(methylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide 
• 417716-93-9 4-(3-chloro-4-(2-fluoroethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 
• 417719-49-4 4-(3-Chloro-4-(2-cyanoethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 
• 857890-39-2 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinoline-carboxamide methanesulfonate 

Relevant articles and documents

Preparation method of lenvatinib and preparation method of lenvatinib intermediate

The invention discloses a preparation method of lenvatinib and a preparation method of a lenvatinib intermediate. The preparation method of an amide compound as shown in a formula II comprises the following step: in a solvent, carrying out amidation react

Preparation method of lenvatinib intermediate

The invention discloses a preparation method of a lenvatinib intermediate. The preparation method comprises the following steps: carrying out a nucleophilic substitution reaction among a compound shown as a formula I, a compound shown as a formula II and

Synthesis method of lenvatinib and new intermediate

The invention discloses a synthesis method of lenvatinib and a new intermediate. The method comprises the following steps: step 1, taking 4-amino-3-chlorophenol hydrochloride and 4-chloro-7-methoxy-6-amido quinoline as initial raw materials, and carrying

Preparation method of high-purity lenvatinib mesylate crystal form C

The invention belongs to the technical field of pharmaceutical chemicals and especially relates to a preparation method of a lenvatinib mesylate crystal form C. According to the method, the conditions of high temperature, acid serving as a solvent and the

PROCESS FOR THE PREPARATION OF LENVATINIB OR ITS SALTS THEREOF

The present invention provides a process for the preparation of Lenvatinib or its salts thereof. The present invention also provides a crystalline form of Lenvatinib, which is characterized by the PXRD pattern as shown in figure 1. The present invention a

NOVEL POLYMORPHS OF 4-[3-CHLORO-4-(N'-CYCLOPROPYL UREIDO)PHENOXY]-7-METHOXYQUINOLINE-6-CARBOXAMIDE, ITS SALTS AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to novel polymorphs of 4-[3-chloro-4-(N'- cyclopropyl ureido) phenoxy]-7- methoxyquinoline- 6- carboxamide methanesulfonate represented by following structural formula-1a and process for preparation thereof. Further, the pres

Preparation method of lenvatinib and its salts

The invention discloses a preparation method of lenvatinib and its salts, wherein N-methylpyrrolidone is used as a reaction solvent in the step of condensation with phenyl chloroformate. The preparation method has the advantages that the danger is success

Preparation method of high-purity lenvatinib and salt thereof

The invention relates to a preparation method of lenvatinib and salt thereof. The adopted method for preparing the lenvatinib has the advantages that the process is simple, the cost is low, the purity is high, the single-purity content meets the regulatio

Method for synthesizing lenvatinib

The invention discloses a method for synthesizing lenvatinib. The method comprises the following steps: with 7-methoxy-4-oxo-1,4-dihydro-quinoline-6-formamide as an initial raw material, carrying outan oxo-arylation reaction on the initial raw material an

Nitrogen-containing aromatic derivatives

Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.